NYSE
$61.50▼ 0.21%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $125.59BShares out 20.400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 10.5After-hours26.10.06 05:184Ownership#●●●
BRISTOL MYERS SQUIBB CO
Bristol Myers Squibb (BMY) insider Cari Gallman filed a Form 4 on October 5, 2026, reporting a change in beneficial ownership of securities as of October 2, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$61.50-0.21%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 05:264Ownership
BRISTOL MYERS SQUIBB CO
Phyllis R. Yale, an insider at Bristol Myers Squibb (BMY), reported changes in beneficial ownership of securities effective September 30, 2026. This filing serves as a standard disclosure regarding the insider's equity holdings.…more
$61.50-0.21%vs prev closeView filingShare - 10.2After-hours26.10.03 05:254Ownership
BRISTOL MYERS SQUIBB CO
Theodore R. Samuels II, an insider at Bristol Myers Squibb (BMY), reported a change in beneficial ownership of company securities as of September 30, 2026. This filing serves as a standard disclosure regarding the executive's stock holdings.…more
$61.50-0.21%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoRegular26.10.24 02:28Bullish#●●●#●●●
Bristol Myers Squibb Shares Fall Following Patient Death in CAR-T Trial…more
Bristol Myers Squibb shares declined after the company reported a patient death in an investigational CAR-T therapy trial. Despite this, the company also presented positive Phase 3 data for its breast cancer treatment candidate.…more
$61.50-0.21%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 1d agoRegular26.10.24 01:22
●●●●●●●● ●●●●● ●●●●●●
Bristol-Myers Squibb stated that the recent Grade 5 adverse event was unrelated to the decision to pause the BreakFree program. The company is working with the FDA to resume patient enrollment by early 2027.…more
$61.50-0.21%vs prev closeShareBenzinga - 1d agoRegular26.10.23 23:33
●●●●●●●● ●●●●● ●●●●●●
Bristol Myers Squibb announced interim safety and efficacy results from the Phase 1 Breakfree-2 study of its CAR-T therapy, zolacabtagene autoleucel, for multiple sclerosis. The data showed a consistent safety profile and promising early efficacy across patient cohorts.…more
$61.50-0.21%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report